Nuveen’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,823,998
| Closed | -$39.1M | – | 3765 |
|
|
2026
Q1 | $39.1M | Buy |
1,823,998
+1,301,543
| +249% | +$18.3M | 0.01% | 763 |
|
|
2025
Q4 | $4.87M | Buy |
522,455
+372,083
| +247% | +$3.11M | ﹤0.01% | 1920 |
|
|
2025
Q3 | $1.06M | Hold |
150,372
| – | – | ﹤0.01% | 2601 |
|
|
2025
Q2 | $977K | Buy |
150,372
+10,714
| +8% | +$73.7K | ﹤0.01% | 2614 |
|
|
2025
Q1 | $1.11M | Sell |
139,658
-1,640
| -1% | -$17.7K | ﹤0.01% | 2594 |
|
|
2024
Q4 | $1.79M | Sell |
141,298
-22,400
| -14% | -$312K | ﹤0.01% | 2432 |
|
|
2024
Q3 | $2.28M | Sell |
163,698
-27,208
| -14% | -$388K | ﹤0.01% | 2346 |
|
|
2024
Q2 | $2.63M | Buy |
190,906
+15,131
| +9% | +$221K | ﹤0.01% | 2249 |
|
|
2024
Q1 | $2.9M | Hold |
175,775
| – | – | ﹤0.01% | 2229 |
|
|
2023
Q4 | $2.57M | Sell |
175,775
-249,434
| -59% | -$3.02M | ﹤0.01% | 2295 |
|
|
2023
Q3 | $5.22M | Buy |
425,209
+72,443
| +21% | +$945K | ﹤0.01% | 1846 |
|
|
2023
Q2 | $4.21M | Sell |
352,766
-146,025
| -29% | -$1.91M | ﹤0.01% | 2007 |
|
|
2023
Q1 | $6.67M | Buy |
498,791
+77,664
| +18% | +$1.52M | ﹤0.01% | 1727 |
|
|
2022
Q4 | $2.79M | Sell |
421,127
-27,643
| -6% | -$567K | ﹤0.01% | 2236 |
|
|
2022
Q3 | $2.97M | Buy |
448,770
+376,218
| +519% | +$8M | ﹤0.01% | 2183 |
|
|
2022
Q2 | $481K | Buy |
72,552
+32,778
| +82% | +$338K | ﹤0.01% | 3024 |
|
|
2022
Q1 | $391K | Buy |
39,774
+24,813
| +166% | +$328K | ﹤0.01% | 3072 |
|
|
2021
Q4 | $260K | Hold |
14,961
| – | – | ﹤0.01% | 3197 |
|
|
2021
Q3 | $355K | Buy |
+14,961
| New | +$359K | ﹤0.01% | 3227 |
|
Other funds holding DAWN
Nuveen's DAWN Position: Q2 2026 in Review
Nuveen sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 1,823,998 shares — an estimated $39.1M sold.
Nuveen first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $39.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Nuveen reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Nuveen sold 1,823,998 Day One Biopharmaceuticals shares in Q2 2026, an estimated $39.1M.
- Nuveen first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- Nuveen's Day One Biopharmaceuticals position peaked at $39.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.